Dianthus Therapeutics, Inc. (DNTH) SEC Filings & Earnings Calls
EquiReason read 16 Dianthus Therapeutics, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-08-04 — Cash and cash equivalents $1.20B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 4.3B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
4 Aug 20268-K · 2.02Cash and cash equivalents $1.20Bearningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q2-2026 | $1.20B |
Risks flagged
Clinical trial risk; no approved products; reliance on pipeline success.
“All programs are investigational; top-line results expected in 2H'28 for gMG.”
4 Aug 202610-QQ2 2026 net loss widened to $50.2M from $31.6M YoY due to increased R&D spending; cash runway extended into 2030 with $1.2B in cash.earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and investments · Q2-2026 | $1.20B | |
| Net loss · Q2-2026 | $-50M | |
| Research and development expenses · Q2-2026 | $49M | +86% y/y |
| General and administrative expenses · Q2-2026 | $14M | +53% y/y |
| License revenue · Q2-2026 | $761000.00 | +294% y/y |
| Interest and investment income · Q2-2026 | $12M | +239% y/y |
Risks flagged
Clinical trial failure risk
“We may never succeed in obtaining regulatory approval for claseprubart, DNTH212, or any other future product candidates.” · word for word
Dependence on capital markets
“We will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources.” · word for word
No product revenue
“Since inception, we have not generated any revenue from product sales, and we do not expect to generate any revenue from the sales of products in the foreseeable future.” · word for word
5 May 202610-QCash, cash equivalents and investments $1.20B; Net loss $-41M; Research and development expenses $35Mopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and investments · Q1-2026 | $1.20B | |
| Net loss · Q1-2026 | $-41M | |
| Research and development expenses · Q1-2026 | $35M | |
| General and administrative expenses · Q1-2026 | $12M | |
| License revenue · Q1-2026 | $463000.00 | |
| Operating cash flow · Q1-2026 | $-29M |
Risks flagged
Clinical trial failure risk
“We may never succeed in obtaining regulatory approval for claseprubart, DNTH212, or any other future product candidates.” · word for word
Capital requirement risk
“We will need additional capital to fund our operations.” · word for word
5 May 20268-K · 2.02Cash, cash equivalents and investments $1.20B; Gross proceeds from public offering $719Mearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and investments · Q1-2026 | $1.20B | |
| Gross proceeds from public offering · Q1-2026 | $719M |
Risks flagged
Clinical-stage company with no approved products; all pipeline candidates in development with regulatory and commercial risks.
“Phase 3 registrational trial of claseprubart on track to initiate in mid-2026; top-line results anticipated in 2H’28”
Dilution from public offering; 719M gross proceeds likely significant share count increase.
“approximately $719 million in gross proceeds from an underwritten public offering of common stock and pre-funded warrants” · word for word
9 Apr 2026DEF 14AProxy statement for 2026 annual meeting; no material event, but reveals strong pay-for-performance alignment and significant capital raises.open
Figures in the filing · each found in the filing text
| Total Stockholder Return (TSR) from Reverse Merger through March 31, 2026 · 2023-09-11 to 20 | 649.0% | |
| Net Loss · FY2025 | $-162M | +91% y/y |
| Net Loss · FY2024 | $-85M | +95% y/y |
| Net Loss · FY2023 | $-44M | |
| CEO Total Compensation · FY2025 | $11M | +20% y/y |
| CEO Compensation Actually Paid · FY2025 | $17M | +39% y/y |
| Average Non-PEO NEO Compensation Actually Paid · FY2025 | $8M | +63% y/y |
| Shares Outstanding · 2026-03-30 | 54,448,771 | |
| Cash Runway · 2026-03 | $2030.00 |
Risks flagged
Clinical trial failure risk
“The company is pre-commercial and relies on clinical trial success; net loss increased to $162M in 2025.”
Dilution risk from equity offerings
“Completed $288M and $719M public offerings in 2025 and 2026, increasing share count significantly.”
26 Mar 20268-K · 8.01FDA agreed to three proposed changes to screening criteria and safety risk classification for claseprubart trials, removing ANA screening and reclassifying SLE risk to DIL.open
Risks flagged
No cases of SLE or DIL observed to date, but reclassification acknowledges potential side effect
“there have been no cases of either SLE or DIL to date in any claseprubart program” · word for word
12 Mar 20268-K · 1.01Dianthus Therapeutics entered into an underwriting agreement to issue and sell 7,313,582 shares of common stock at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999 per share, with net proceeds expected to be approximatopen
Figures in the filing · each found in the filing text
| Net Proceeds | $674M | |
| Shares Offered | 7,313,582 | |
| Pre-Funded Warrants | 402,468 | |
| Underwriter Option Shares | 1,157,407 | |
| Public Offering Price per Share | $81.00 |
Risks flagged
Significant dilution from equity offering
“7,313,582 shares + 402,468 pre-funded warrants + 1,157,407 option shares”
9 Mar 202610-KNet loss $-162M; Revenue $2M; Research and development expenses $146Mopen
Figures in the filing · each found in the filing text
| Net loss · FY2025 | $-162M | |
| Revenue · FY2025 | $2M | |
| Research and development expenses · FY2025 | $146M | |
| General and administrative expenses · FY2025 | $34M | |
| Cash, cash equivalents and investments · 2025-12-31 | $514M | |
| Net cash used in operating activities · FY2025 | $-129M |
Risks flagged
Clinical trial failure risk
“If we are required to conduct additional clinical trials or other testing of claseprubart, DNTH212 or any other product candidates beyond those that we contemplate, if we unable to successfully complete clinical trials of claseprubart, DNTH212 or any other product candidates, if the results of these trials are not positive or are only moderately positive or ” · word for word
Single-source CDMO dependency
“We currently have a sole source relationship with WuXi Biologics for our supply of claseprubart.” · word for word
No product revenue or profitability
“We have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from operations.” · word for word
9 Mar 20268-K · 2.02, 7.01, 8.01Cash, cash equivalents and investments $514M; R&D expenses $146M (+75% y/y); G&A expenses $34Mearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and investments · FY2025 | $514M | |
| R&D expenses · FY2025 | $146M | +75% y/y |
| G&A expenses · FY2025 | $34M |
Risks flagged
Pre-revenue biotech; clinical and regulatory risks for pipeline.
“No approved products; pipeline in Phase 2/3.”
12 Jan 20268-K · 2.02, 7.01Cash, cash equivalents and short-term investments $514Mearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and short-term investments · Q4-2025 | $514M |
Risks flagged
Preliminary cash estimate subject to change; clinical trial risks.
“preliminary and unaudited” · word for word
5 Nov 202510-QDianthus Therapeutics reported Q3 2025 financial results, including a net loss of $36.8M, and highlighted positive Phase 2 data for claseprubart and a $288.4M public offering.earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and investments · Q3-2025 | $556M | |
| Net loss · Q3-2025 | $-37M | |
| Research and development expenses · Q3-2025 | $32M | |
| General and administrative expenses · Q3-2025 | $8M | |
| Revenue · Q3-2025 | $396000.00 | |
| Gross proceeds from public offering · Q3-2025 | $288M |
Risks flagged
Clinical trial failure risk
“If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.” · word for word
Need for additional capital
“We will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources.” · word for word
5 Nov 20258-K · 2.02Cash $525Mearningsopen
Figures in the filing · each found in the filing text
| Cash · Q3-2025 | $525M |
Risks flagged
Clinical-stage biotech with no approved products; regulatory and clinical trial risk.
Dianthus Therapeutics, Inc. — questions
- What did Dianthus Therapeutics, Inc. file recently?
- 16 SEC filings in the last 12 months. Latest: 8-K on 2026-08-04 — Cash and cash equivalents $1.20B
Every figure on this page comes from Dianthus Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.